



July 21, 2021

Santen to Present Latest Data on STN2000100  
at 2021 ASCRS Annual Meeting

Santen Pharmaceutical Co., Ltd. (Head Office in Osaka, hereinafter “Santen”) announced today that some publications related to the glaucoma surgical device, STN2000100 (DE-128) will be presented at the American Society of Cataract and Refractive Surgery annual meeting (2021 ASCRS; <https://annualmeeting.ascrs.org/>) from July 23 to 27, 2021.

STN2000100 has been launched in Europe as *PRESERFLO MicroShunt* and Santen successively filed for marketing approval in Asia. Santen submitted the Premarket Approval (PMA) application in the U.S. In the conference, some presentations including sub-analysis data from a clinical study in the U.S. and Europe, INN-005, will be conducted.

In addition, Glaukos Corporation (San Clemente, CA, U.S.) is responsible for developing and selling products in the Americas, Australia, and New Zealand (press release on May 19, 2021; <https://www.santen.com/en/news/20210519-1.pdf>).

Presentation topics

Poster ID	Date and time	Presentation title
77191	July 23, 2021 7:00–8:00 PM (PDT)	MicroShunt versus Trabeculectomy in Primary Open-angle Glaucoma: 1-year, Single-site Outcomes from a Randomized Study
77192	July 23, 2021 7:00–8:00 PM (PDT)	MicroShunt and Trabeculectomy Surgery in High-risk Primary Open-angle Glaucoma: 1-year Outcomes from a Randomized Study

For abstracts, please see the following link:

<https://ascrs.confex.com/ascrs/21am/meetingapp.cgi/Home/0>

Contact:

Investor Relations Group

Santen Pharmaceutical Co., Ltd.

E-mail: [ir@santen.com](mailto:ir@santen.com)